AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys-Reference-Cited by-同舟云学术

AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys

Published:2014-11 Issue:11 Volume:20 Page:1119-1123
ISSN:1353-8020
Container-title:Parkinsonism & Related Disorders
language:en
Short-container-title:Parkinsonism & Related Disorders

Author:

Di Paolo Thérèse,Grégoire Laurent,Feuerbach Dominik,Elbast Walid,Weiss Markus,Gomez-Mancilla Baltazar

Funder

Novartis Pharmaceuticals, Basel, Switzerland

Publisher

Elsevier BV

Subject

Clinical Neurology,Geriatrics and Gerontology,Neurology

Reference18 articles.

1. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature;Ahlskog;Mov Disord,2001

2. Clinical aspects and management of levodopa-induced dyskinesia;Tambasco;Parkinsons Dis,2012

3. Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesias in a rat model of Parkinson's disease;Bordia;J Pharmacol Exp Ther,2008

4. Nicotinic receptor agonists decrease l-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats;Huang;Neuropharmacology,2011

5. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys;Quik;Ann Neurol,2007

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia;Neuropharmacology;2024-05

2. Novel and experimental therapeutics for the management of motor and non-motor Parkinsonian symptoms;Neurological Sciences;2024-02-23

3. Nicotinic Acetylcholine Receptor Dysfunction in Addiction and in Some Neurodegenerative and Neuropsychiatric Diseases;Cells;2023-08-11

4. Physiologic Functions and Therapeutic Applications of α7 Nicotinic Acetylcholine Receptor in Brain Disorders;Pharmaceutics;2022-12-22

5. Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease;Drugs;2022-07